Managing breast cancers with low estrogen receptor and HER2 by drugging both.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24352641.
- Also identified by DOI 10.1158/1078-0432.CCR-13-2994 and PMC identifier 3946528.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Low estrogen receptor (ER) levels in breast tumors are associated with poorer response to antiestrogen therapy. Finn and colleagues identify low ER levels as a biomarker predicting benefit from the addition of the EGFR/HER2 dual inhibitor lapatinib to an antiestrogen treatment regimen in patients with metastatic ER(+)/HER2(-) breast cancer.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Breast Neoplasms
- Quinazolines
- Receptors, Estrogen
- Receptors, Progesterone